5-HT2C Receptor Agonist Anorectic Efficacy Potentiated by 5-HT1B Receptor Agonist Coapplication: An Effect Mediated via Increased Proportion of Pro-Opiomelanocortin Neurons Activated
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
An essential component of the neural network regulating ingestive behavior is the brain 5-hydroxytryptamine2C receptor (5-HT2CR), agonists of which suppress food intake and were recently approved for obesity treatment by the US Food and Drug Administration. 5-HT2CR-regulated appetite is mediated primarily through activation of hypothalamic arcuate nucleus (ARC) pro-opiomelanocortin (POMC) neurons, which are also disinhibited through a 5-HT1BR-mediated suppression of local inhibitory inputs. Here we investigated whether 5-HT2CR agonist anorectic potency could be significantly enhanced by coadministration of a 5-HT1BR agonist and whether this was associated with augmented POMC neuron activation on the population and/or single-cell level. The combined administration of subanorectic concentrations of 5-HT2CR and 5-HT1BR agonists produced a 45% reduction in food intake and significantly greater in vivo ARC neuron activation in mice. The chemical phenotype of activated ARC neurons was assessed by monitoring agonist-induced cellular activity via calcium imaging in mouse POMC-EGFP brain slices, which revealed that combined agonists activated significantly more POMC neurons (46%) compared with either drug alone (∼25% each). Single-cell electrophysiological analysis demonstrated that 5-HT2CR/5-HT1BR agonist coadministration did not significantly potentiate the firing frequency of individual ARC POMC-EGFP cells compared with agonists alone. These data indicate a functional heterogeneity of ARC POMC neurons by revealing distinct subpopulations of POMC cells activated by 5-HT2CRs and disinhibited by 5-HT1BRs. Therefore, coadministration of a 5-HT1BR agonist potentiates the anorectic efficacy of 5-HT2CR compounds by increasing the number, but not the magnitude, of activated ARC POMC neurons and is of therapeutic relevance to obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 2×
“…5-HT and the adipocytederived hormone leptin reciprocally regulate the activity of POMC and AgRP neurons by directly activating POMC neurons, inhibiting GABAergic inputs onto POMC neurons, and directly inhibiting AgRP neurons (Cowley et al., 2001; Heisler et al., 2002, 2006; Zhou et al., 2005).”
BackgroundValvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632 · cited 1×
“However, such compounds have been withdrawn from clinical use due to off-target effects (Connolly et al., 1997).”
BackgroundMulticenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 1×
“Lorcaserin, a 5-HT2CR agonist soon to reach the clinical setting (Smith et al., 2010), was the first new approved obesity treatment by the FDA in 13 years.”
BackgroundAlon, T., Zhou, L., Pérez, C. A., Garfield, A. S., Friedman, J. M., & Heisler, L. K. (2009) · Endocrinology · doi:10.1210/en.2009-0881 · Cited by 70 · cited 1×
“9% saline and then 10% neutral buffered formalin (Sigma), and brains were extracted, prepared, coronally sectioned (25 m), and processed for cFOS immunoreactivity (FOS-IR) as described previously (Alon et al., 2009; Lam et al., 2009; Marston et al., 2011) using an anti-cFOS rabbit primary antibody (1:8000, catalog #PC…”
MethodSelf-citation
Cited by
Genetics and epigenetics of eating disorders
Bulik, C., Yilmaz, Z., & HArdaway, A. (2015) · Advances in Genomics and Genetics · doi:10.2147/agg.s55776 · Cited by 278
Nucleus of the Solitary Tract Serotonin 5-HT2C Receptors Modulate Food Intake
D'Agostino, G., Lyons, D., Cristiano, C., Lettieri, M., Olarte-Sanchez, C., Burke, L. K., Greenwald-Yarnell, M., Cansell, C., Doslikova, B., Georgescu, T., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.017 · Cited by 149
Self-citationA talk between fat tissue, gut, pancreas and brain to control body weight
Wilson, J. L., & Enriori, P. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.08.022 · Cited by 39
Metadata
- Authors
- Doslikova, B., Garfield, A. S., Shaw, J., Evans, M. L., Burdakov, D., Billups, B., & Heisler, L. K.
- Venue
- Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2013-06-05
- Volume
- 33
- Issue
- 23
- Pages
- 9800-9804
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1967117235
- Cited by
- 57
- References
- 4
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 5-HT2C Receptor Agonist Anorectic Efficacy Potentiated by 5-HT1B Receptor Agonist Coapplication: An Effect Mediated via Increased Proportion of Pro-Opiomelanocortin Neurons Activated. https://app.cochat.ai/papers/10.1523/jneurosci.4326-12.2013
- The paper
- Doslikova, B., Garfield, A. S., Shaw, J., Evans, M. L., Burdakov, D., Billups, B., & Heisler, L. K. (2013). 5-HT2C Receptor Agonist Anorectic Efficacy Potentiated by 5-HT1B Receptor Agonist Coapplication: An Effect Mediated via Increased Proportion of Pro-Opiomelanocortin Neurons Activated. Journal of Neuroscience. https://doi.org/10.1523/jneurosci.4326-12.2013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.